A ppropriate patient selection is a key step in the performance of efficient and ethical clinical trials (1, 2) . As expenditures required to perform clinical trials increase and such trials become ever more complex (3) , the need to minimize required sample size becomes ever more pressing. Enrolling patients at low risk of death in a clinical trial using mortality as an end point results in an increased sample size required to detect a beneficial effect for novel therapies (2) . In addition, the responsibilities of performing human research dictate that patients who are unlikely to benefit from a given therapeutic intervention should not be offered enrollment in a clinical trial, particularly when that trial involves more than minimal risk. At the present time, for clinical syndromes such as sepsis, we have limited ability to accurately predict mortality at intensive care unit admission. Clinical prediction systems may be helpful on a population basis (4); however, for individual patients, clinical predictive scoring systems often fall short (5) . Thus, novel means of risk stratification for patients before enrollment in clinical trials of novel therapies in critical illness are needed.
Plasma biomarkers provide a potentially useful approach to risk stratification of patients before enrollment in clinical trials (6, 7) . For instance, a biomarker that excludes subjects at low risk of mortality could be useful in selecting a higher risk subgroup for enrollment in clinical trials, thus improving the riskbenefit ratio and reducing the necessary sample size. Although the use of biologic markers to stratify risk for patients for enrollment in clinical trials is not currently common in critical care, in other fields such as oncology, biologic markers are routinely used to triage patients for enrollment in trials of novel therapies (8) . Such an approach may be particularly useful in the setting of a syndrome like sepsis or acute lung injury that is Objective: Plasma interleukin-8 levels of <220 pg/mL have an excellent negative predictive value (94% to 95%) for death at 28 days in children with septic shock and thus may be useful for risk stratification in clinical trial enrollment in this population. Whether plasma interleukin-8 would have similar utility in adults with septic shock is unknown.
Design: Analysis of plasma interleukin-8 levels and prospectively collected clinical data from patients enrolled in two large randomized controlled trials of ventilator strategy for acute lung injury.
Setting: Intensive care units of university hospitals participating in the National Institutes of Health Acute Respiratory Distress Syndrome Network.
Patients: One hundred ninety-two adult patients with vasopressor-dependent septic shock.
Interventions: None. Measurements and Main Results: Plasma interleukin-8 levels >220 pg/mL were significantly associated with death at 28 days in this cohort (odds ratio, 2.92; 95% confidence interval, 1.42 to 5.99; p ‫؍‬ .001). However, in contrast to the findings in pediatric septic shock, a plasma interleukin-8 cutoff <220 pg/mL had a negative predictive value for death of only 74% (95% confidence interval, 66% to 81%) in adults with septic shock. Receiver operating characteristic analysis found an area under the curve of 0.59 for plasma interleukin-8, indicating that plasma interleukin-8 is a poor predictor of mortality in this group. In adults aged <40 yrs, a plasma interleukin-8 cutoff <220 pg/mL had a negative predictive value of 92%.
Conclusions: In contrast to similar pediatric patients, plasma interleukin-8 levels are not an effective risk stratification tool in older adults with septic shock. Future studies of biomarkers for risk stratification in critically ill subjects will need to be replicated in multiple different populations before being applied in screening for clinical trials. (Crit Care Med 2010; 38:1436 -1441) KEY WORDS: interleukin-8; acute lung injury; sensitivity; specificity; negative predictive value; risk stratification defined by clinical criteria and therefore somewhat heterogenous (6, 7) . Many plasma biomarkers can be measured relatively quickly and using a small amount of plasma (as little as 20 L for some assays) and thus may be practical tools for screening and risk stratification (9) .
Interleukin-8 (IL-8) is the main neutrophil chemokine and activator in humans and has been previously associated with both severity of disease and poor clinical outcomes in adults and children with sepsis and septic shock (10 -13) . In children with septic shock, a plasma IL-8 cutoff of Ͻ220 pg/mL identified subjects with a low risk of death with a negative predictive value of 94% to 95% for 28-day mortality in separate derivation and validation cohorts (14) . We hypothesized that plasma IL-8 levels would have similar utility in risk stratification in adults with septic shock and tested this hypothesis in patients with septic shock enrolled in large randomized clinical trials of acute lung injury (ALI).
MATERIALS AND METHODS
Clinical data and biologic samples were obtained from patients enrolled in the National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network's randomized controlled trials of lower tidal volume ventilation (15) and higher vs. lower positive end-expiratory pressure (16) . Details of the original trials have been previously published in full.
Briefly, the first study enrolled 861 patients to test the hypothesis that ventilation with a low tidal volume, plateau pressurelimited strategy would reduce mortality in patients with ALI (15) . The trial demonstrated a significant reduction in 180-day mortality in the low tidal volume treatment group (31% vs. 40%, p ϭ .007); once the benefit of the lower tidal volume strategy had been demonstrated, an additional 41 patients were assigned to the lower tidal volume to complete a factorialized trial of lisofylline versus placebo (17) , and these patients are also included in this analysis. Patients treated with the higher tidal volume strategy were excluded from the primary analysis as a result of the effect of higher tidal volume on mortality. Clinical data and plasma samples for biomarker measurements were collected at baseline before randomization; all patients were followed until death, 180 days, or until discharge home with unassisted breathing, whichever occurred first.
The second study enrolled 549 patients to test the hypothesis that higher levels of positive end-expiratory pressure would reduce mortality in patients with ALI (16) . Clinical data and plasma samples for biomarker measurements were collected at baseline before randomization; patients were followed until death, day 90, or discharge home with unassisted breathing. The Data Safety and Monitoring Board terminated the trial after enrollment of 549 patients on the basis of futility. The trial found no difference in 90-day mortality and no modulation of circulating interleukin-6, surfactant protein D, or interstitial cell adhesion molecule-1 with higher vs. lower levels of positive end-expiratory pressure.
The etiology of ALI was determined in both trials by the site investigator; in cases in which more than one potential cause of ALI was present, the site investigator then determined the principal cause. For this analysis, patients were defined as having septic shock if both of the following criteria were met: 1) the primary etiology of ALI was classified as either sepsis or pneumonia; and 2) the patient required vasopressor therapy in the 24 hrs before randomization. Subjects missing data on vasopressor use over the prior 24 hrs were considered not to have vasopressor-dependent shock. In a separate sensitivity analysis, we used an alternative time window to define septic shock as follows: 1) the primary etiology of ALI was classified as either sepsis or pneumonia; and 2) the patient required vasopressor therapy at any point from the time of randomization until midnight the same day. Ventilator-free days were defined as the number of days between 0 and 28 that the patient was free from mechanical ventilation if the patient tolerated at least 48 hrs without mechanical ventilation.
Biologic Assay. Plasma IL-8 levels were measured on baseline, preintervention samples using a commercially available enzymelinked immunoassay (R&D Systems, Minneapolis, MN). Plasma measurements were made on the basis of plasma availability and have been previously described in other analyses (18, 19) .
Statistical Methods. Statistical analysis was performed with Stata 10.0 (College Station, TX). We used 28-day mortality as the primary end point of the study, like in prior studies of IL-8 in pediatric sepsis (14) . Pre hoc power analysis demonstrated a power of 91% to detect an odds ratio for mortality of Ն4.0 for an IL-8 cutoff of 220 pg/mL (as was demonstrated in the original pediatric study). Data from the two original Acute Respiratory Distress Syndrome Network studies was combined for this analysis. Categorical data were analyzed using the chi-square test or Fisher's exact test. Normally distributed continuous variables were analyzed using the Student's t test or analysis of variance. Nonparametric continuous variables were analyzed using the Kruskal-Wallis test or Wilcoxon rank sum. Pairwise comparisons after chi-square, analysis of variance, or Kruskal-Wallis tests were adjusted using the Bonferroni correction for multiple comparisons. Alpha was set at 0.05 for all analyses, and two-tailed tests of hypothesis were used throughout.
RESULTS
From the original cohort of 1451 subjects, 297 had evidence of vasopressordependent septic shock. After excluding patients treated with a higher tidal volume strategy (n ϭ 92), patients in whom plasma quantities were insufficient to measure IL-8 (n ϭ 22, ten of whom were also treated with higher tidal volumes), and patients aged Ͻ18 yrs (n ϭ 1), 192 subjects with vasopressor-dependent septic shock were included in this analysis. The clinical characteristics of these patients are compared with those of other trial participants and with patients with vasopressor-dependent shock who were excluded as a result of missing IL-8 data or the use of higher tidal volumes in Table 1 . As compared with the remainder of the cohort, included subjects with vasopressor-dependent septic shock had significantly higher severity of illness scores and fewer ventilator-free days as well as higher IL-8 levels. There were no significant differences between included and excluded patients with vasopressordependent septic shock. As in prior studies, plasma IL-8 was associated with severity of illness scores (Acute Physiology and Chronic Health Evaluation III, r ϭ 0.23; p ϭ .002) and the number of organ failure-free days (r ϭ Ϫ0.23; p ϭ .002) in included subjects with septic shock.
Given the demonstrated utility of a cut point of 220 pg/mL in subjects with pediatric septic shock, we dichotomized baseline plasma IL-8 levels as Ն220 pg/mL or Ͻ220 pg/mL and tested the value of this cutoff for mortality prediction in this cohort (Fig. 1 ). Although the association between IL-8 levels Ն220 pg/mL and death was statistically significant (odds ratio, 2.92; 95% confidence interval, 1.42 to 5.99; p ϭ .001), the sensitivity and negative predictive value compared unfavorably with the results in pediatric septic shock (Fig. 1) . In particular, the negative predictive value of the plasma IL-8 cutoff, which was 94% to 95% in pediatric septic shock, was 74% (95% confidence interval, 66% to 81%) in this population.
To determine whether the optimal cut point for plasma IL-8 levels might differ in adult subjects compared with pediatric subjects, we used receiver operating characteristic analysis (Fig. 2) . This analysis demonstrated that plasma IL-8 pro-vides poor discrimination in this population regardless of the exact cutoff used with an area under the curve of 0.59 (95% confidence interval, 0.52 to 0.66).
As a sensitivity analysis, we sought to determine whether vasopressor use nearer the time of plasma sampling would more accurately define the population of patients with septic shock. For this analysis, subjects were defined as having septic shock if they required vasopressors at any point from the time of randomization (and plasma sampling) until midnight the same day and had ALI as a result of either sepsis or pneumonia. This definition generated a total of 206 patients with vasopressor-dependent septic shock. The use of this alternative definition for septic shock did not substantially affect the sensitivity, specificity, or positive or negative predictive value of the IL-8 cutoff of 220 pg/mL. Likewise, the inclusion of patients ventilated with higher tidal volumes did not substantively affect the test performance characteristics (data not shown).
Because the prior data supporting an IL-8 cutoff of 220 pg/mL came from a pediatric population, we separately analyzed the value of this cutoff in subjects in our data set between 18 and 40 yrs of age (Fig. 3 ). In this subgroup (n ϭ 45) with mortality of 13%, an IL-8 cutoff of 220 pg/mL had a negative predictive value of 92% (95% confidence interval, 78% to 98%). Likewise, the area under the curve in receiver operator characteristic analysis was 0.83 (95% confidence interval, 0.68 to 0.92), indicating fairly good discrimination in this subset of patients.
DISCUSSION
In contrast to prior studies in pediatric patients with sepsis, we found that a plasma IL-8 of Ͻ220 pg/mL was not an effective tool for detecting older adult patients with septic shock at low risk of death at 28 days. This result contrasts sharply with the previously reported finding that this IL-8 cutoff had a high negative predictive value for mortality in pediatric patients with septic shock (14) . Although plasma IL-8 levels Ն220 pg/mL were significantly associated with death at 28 days in this cohort, the association was much weaker than in the previous pediatric study with a much smaller area under the receiver operator curve (0.59 compared with 0.86). In the subgroup of patients aged Ͻ40 yrs, an IL-8 cutoff of All values represent no. (%) unless otherwise specified. Data were missing on 13 subjects for chronic health information, one subject for P:F ratio, nine subjects for ventilator-free days, and 142 subjects for IL-8. Subjects with vasopressor-dependent septic shock were excluded for the following reasons: use of high tidal volume ventilation, age Ͻ18 years, or lack of IL-8 data. All p values below are corrected for multiple comparisons.
a Comparison with remainder of cohort: p ϭ .01; comparison with excluded patients with vasopressor-dependent septic shock: p ϭ 1.0; b comparison with remainder of cohort: p Ͻ .001; comparison with excluded patients with vasopressor-dependent septic shock: p ϭ .39; c comparison with both remainder of cohort and excluded patients nonsignificant; d comparison with remainder of cohort: p ϭ .003; comparison with excluded patients with vasopressor-dependent septic shock: p ϭ .17; e comparison with remainder of cohort: p Ͻ .0001; comparison with excluded patients with vasopressordependent septic shock: p ϭ .4.
Figure 1.
Contingency table demonstrating association between high plasma interleukin (IL)-8 levels and mortality at 28 days in adults with vasopressor-dependent septic shock. CI, confidence interval. value comparable to that previously reported in pediatric patients, although the size of this group was relatively small.
Why might the results of our study of plasma IL-8 in adult patients with septic shock differ so considerably from those of the prior pediatric study? Several explanations are possible. First, the pathophysiology and predictors of mortality in older adult and pediatric septic shock may differ considerably. The finding that plasma IL-8 performed well in subjects Ͻ40 yrs of age in our cohort supports this interpretation of the data. Mortality in adults with septic shock is strongly driven by the presence of underlying comorbidities such as acquired immunodeficiency syn-drome, cancer, liver disease, and immunosuppression (4). In contrast, in children with sepsis, acute severity of illness seems to be a stronger predictor of mortality, with many children previously healthy before developing septic shock (20, 21) . Likewise, the majority of adult patients with severe sepsis are Ն65 yrs of age with increasing age a risk factor for death in adults but not in children (22, 23) . Also, decisions regarding end-of-life care and withdrawal of support likely differ substantially in adults and children with major implications for mortality because 90% of deaths in adult intensive care units are preceded by withdrawal of life support (24, 25) . These differences in the determinants 1 of severity of illness and aggressiveness of support may significantly affect the performance of IL-8 as a predictor of 28-day mortality in older adult patients. Interestingly, among included patients with vasopressor-dependent septic shock, plasma IL-8 was as strongly associated with organ failurefree days in adults Ͻ40 yrs of age as in older adults (data not shown), providing further suggestion that underlying comorbidities and/or end-of-life decisions may be partially responsible for differences in IL-8's prognostic value in these age groups.
Second, septic shock was not prospectively defined in the Acute Respiratory Distress Syndrome Network studies; rather, we used clinical data prospectively collected on the presence of sepsis or pneumonia, concurrent with the requirement for vasopressors, to define septic shock. This approach may result in a slightly different population than a prospective assessment for septic shock would have; in particular, the patients selected by our method may have more severe disease, thus affecting the prevalence of mortality in the sample and the negative predictive value as a result, as further detailed subsequently.
Third, the timing of sampling relative to the onset of septic shock may differ in the two populations studied. In the original pediatric sepsis paper by Wong et al (14) , plasma IL-8 levels were drawn within 24 hrs of intensive care unit admission, an ideal timeframe for the development of biomarker-based stratification tools. In contrast, in the current study population, plasma IL-8 samples were drawn within 36 hrs of the onset of ALI; however, data on the timing of the onset of sepsis and/or pneumonia were unavailable. Although relatively little is known about the clearance and kinetics of plasma IL-8, levels may have declined rapidly after the onset of sepsis, making even small differences in timing of sampling relevant to the predictive value of IL-8 (26, 27) .
Fourth, changes in the prevalence of a condition (in this case, an outcome) may affect the positive and negative predictive values of a diagnostic test; the more common a disease is in the population studied, the less likely a positive test result is to be a "false-positive." Put differently, increased prevalence of a condition is expected to lead to an increase in the positive predictive value of a diagnostic test and a similar decrease in the negative predictive value of the test (28) . While the mortality rate in pediatric severe sepsis is 10% (22) , mortality in adults with septic shock is 18% to 20% in general, and mortality in the patients we studied with septic shock was 33% (29) . Thus, our findings of a higher positive predictive value and lower negative predictive value of an IL-8 cutoff of 220 pg/mL in adults as compared with children align with the expected effect of the higher prevalence of mortality in this group. This result emphasizes the issues with generalizability that may arise when attempting to apply diagnostic test results to populations with differing prevalences of disease.
What implications does this "negative" result have for future study of biomarkers as risk stratification tools in clinical trials in the intensive care unit? Although plasma IL-8 certainly cannot be applied on the basis of these results as a screening tool for clinical trials in adult patients with septic shock, the theoretical rationale for using a biomarker in this manner remains strong (7) . In oncology (8) and cardiovascular medicine (30) , biomarkers are routinely used as entry criteria for clinical trials with excellent results; thus, the search for similar markers in critical illness should not be abandoned. At the same time, our results point out the importance of studying diverse populations to ensure the generalizability of a result before markers are used in either clinical practice or clinical trials.
The strengths of our study include its multicenter nature, including a geographically diverse set of intensive care units across the United States, the diversity of racial and ethnic groups and gender balance of the subjects, and the strength of the clinical data, which was collected within the framework of a randomized controlled trial and as such should be of high fidelity. This study has some limitations as well. First, as mentioned, septic shock was not prospectively defined in the database we used. Both sepsis and vasopressor use were prospectively defined; furthermore, sensitivity analyses varying the timing of vasopressor requirements yielded similar results to our primary analysis. Nevertheless, this retrospective definition applied to prospectively collected data may have altered the spectrum of disease we were able to capture. Second, by definition, all the patients we studied with septic shock also had ALI, which may have affected the predictive value of IL-8 levels in this co-hort. Although we excluded patients randomized to the higher tidal volume arm of the original Acute Respiratory Distress Syndrome Network trial, it is possible that baseline IL-8 levels could have been affected by prerandomization ventilator strategy or other biologic processes unique to ALI, thus diluting their predictive value for septic shock-related mortality. Finally, the assay used to measure IL-8 in plasma differed between this study and the prior pediatric publication. The previous pediatric IL-8 study used an IL-8 enzyme-linked immunosorbent assay kit from Biosource (Camarillo, CA) in some patients and a multiplexing platform (Flowmetrix; Dynamic Systems Solutions, Herndon, VA) in others. Our study used an IL-8 enzyme-linked immunosorbent assay purchased from R&D Systems (Minneapolis, MN). These different assays may have contributed to differences in absolute biomarker values between the two populations.
In conclusion, a plasma IL-8 cutoff of 220 pg/mL in adult patients with septic shock did not adequately identify patients at low risk of death at 28 days, in stark contrast to prior results in the pediatric septic shock population. Although the future of using biomarkers as screening tools for clinical trials in the intensive care unit remains bright, these results highlight the importance of replicating intriguing results in related but different patient populations.
